Posted by Michael Wonder on 22 Feb 2024
Artiva Biotherapeutics receives FDA fast track designation for AlloNK in lupus nephritis
22 February 2024 - Artiva Biotherapeutics announced today that the US FDA has granted fast track designation to Artiva’s lead program AlloNK (also known as AB-101) for the treatment of lupus nephritis in combination with rituximab or obinutuzumab.
AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate that enhances the activity of B-cell-targeting monoclonal antibodies to drive B-cell depletion.
